

1 **The time between vaccination and infection impacts immunity against** 2 **SARS-CoV-2 variants**

3 Timothy A. Bates¹, Hans C. Leier¹, Savannah K. McBride¹, Devin Schoen², Zoe L. Lyski¹, David
4 X. Lee¹, William B. Messer^{1,2,3,#}, Marcel E. Curlin^{2,#}, Fikadu G. Tafesse^{1,#}

5 ¹Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR
6 97239, United States. ²Division of Infectious Diseases, Oregon Health & Science University; Portland, OR
7 97239, United States. ³OHSU-PSU School of Public Health, Oregon Health & Science University; Portland,
8 OR 97239, United States

9

10 #Corresponding authors

11 Fikadu G. Tafesse – tafesse@ohsu.edu

12 Marcel E. Curlin – curlin@ohsu.edu

13 William B. Messer – messer@ohsu.edu

14

15 **Abstract**

16 As the COVID-19 pandemic continues, long-term immunity against SARS-CoV-2 will be globally
17 important. Official weekly cases have not dropped below 2 million since September of 2020, and
18 continued emergence of novel variants have created a moving target for our immune systems
19 and public health alike. The temporal aspects of COVID-19 immunity, particularly from repeated
20 vaccination and infection, are less well understood than short-term vaccine efficacy. In this study,
21 we explore the impact of combined vaccination and infection, also known as hybrid immunity, and
22 the timing thereof on the quality and quantity of antibodies produced by a cohort of 96 health care
23 workers. We find robust neutralizing antibody responses among those with hybrid immunity
24 against all variants, including Omicron BA.2, and we further found significantly improved
25 neutralizing titers with longer vaccine-infection intervals up to 400 days. These results indicate
26 that anti-SARS-CoV-2 antibody responses undergo continual maturation following primary
27 exposure by either vaccination or infection for at least 400 days after last antigen exposure. We
28 show that neutralizing antibody responses improved upon secondary boosting with greater impact
29 seen after extended intervals. Our findings may also extend to booster vaccine doses, a critical
30 consideration in future vaccine campaign strategies.

31 Introduction

32 Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late
33 2019, the coronavirus disease 2019 (COVID-19) pandemic has continued to expand and contract
34 at regular intervals, and it remains an ongoing threat to global public health. As of August 2022,
35 the number of officially recognized cases is approaching 600 million,¹ and the true number of
36 people with at least one previous infection is likely much higher with estimates upwards of 3.4
37 billion, 44% of the global population, even before the emergence of the Omicron variant.² Due to
38 ongoing transmission and the continued emergence of novel SARS-CoV-2 variants, it is likely that
39 this number will continue to rise despite large-scale public health control efforts. Nevertheless,
40 current vaccines have proven to be invaluable tools for protecting public health and have saved
41 countless lives.

42 First generation lipid nanoparticle mRNA vaccines including Comirnaty (Pfizer-BioNTech,
43 previously BNT162b2) and Spikevax (Moderna, previously mRNA-1273) became available in the
44 United States in December, 2020, and to this day remain the most utilized vaccines in many parts
45 of the world.³ These vaccines are both well established as providing temporary prevention of
46 SARS-CoV-2 infection as well as longer-term protection from severe COVID-19 and death.^{4,5} The
47 primary challenges faced by vaccination-based protection at this stage in the pandemic are
48 antibody waning and the emergence of concern (VOCs).^{6,7} Additional vaccine boosters given
49 months after initial vaccination have been shown to provide partial protection against novel
50 variants including Omicron.^{8,9} However, the most protective immune responses are seen after a
51 combination of vaccination and natural infection, also known as hybrid immunity.¹⁰⁻¹³

52 Several key variables influence the protective efficacy of SARS-CoV-2 immunity. The first is the
53 mechanisms by which immunity is elicited, which may include natural infection or vaccination with
54 any of the different vaccine types.^{13,14} The second is viral antigenic variation, which encompasses
55 differences in the amino acid sequence and post-translational modification of viral antigens
56 depending on which variant of SARS-CoV-2 the antigens were derived from.^{15,16} The third is timing
57 between repeat exposures, including the interval between vaccine doses and the much less
58 studied interval between vaccination and natural infection.¹⁷⁻²⁰ Additionally, the length of time
59 since last exposure can lead to waning immunity and decreased protection. However, the
60 durability of responses from different exposure modes can vary greatly.^{13,21,22} Finally, other
61 variables exist which have important implications for immunity including a person's age, sex, and
62 comorbidities, and certain therapeutic agents. Understanding the impact of these variables is key
63 for risk-stratifying populations and guiding general vaccination strategies.

64 As the pandemic continues, separating these variables' individual contributions to immunity
65 becomes increasingly complex, particularly as global efforts to track infections lose momentum.
66 Further, as SARS-CoV-2 transitions to a globally endemic virus, hybrid immunity from combined
67 vaccination and natural infection will be the dominant form of immunity, and while hybrid immunity
68 is currently the subject of intense focus, very little work has been done thus far to determine the
69 impact of exposure timing on its development.

70 Here, we report results of studies of 2 cohorts: the first is comprised of individuals recovered from
71 COVID-19 and paired infection naïve, vaccinated controls from whom serum samples were
72 collected both before and after vaccination; the second cohort builds on our experience from the
73 first cohort and includes vaccinated individuals with prior COVID-19, vaccinated individuals that
74 then experienced breakthrough infection, and infection naïve vaccinated controls. The second
75 cohort includes individuals with a wide range of intervals (35-404 days) between PCR-confirmed
76 COVID-19 and vaccination. We utilized enzyme-linked immunosorbent assays (ELISA) and live-
77 virus neutralization assays with the original SARS-CoV-2 (WA1) and the variants of concern

78 (Alpha, Beta, Gamma, Delta, Omicron BA.1, and Omicron BA.2) to discern how the interval
79 between vaccination and infection affects the resulting level of humoral immunity. We find that
80 the magnitude, potency, and breadth of the hybrid immune response against variants continue to
81 improve for at least 400 days. These results suggest that the primary immune response to either
82 vaccination or natural infection continues developing for over a year after first exposure, in the
83 absence of additional exposures and that boosting with the vaccine or infection leads to a hybrid
84 immunity with dramatically improved antibody quantity and quality as measured by their capacity
85 to recognize and neutralize emergent SARS-CoV-2 variants.

86 **Results**

87 ***A longitudinal cohort of vaccinees with previous COVID-19 displayed improved SARS-*** 88 ***CoV-2 neutralization compared to vaccination alone.***

89 Between December 2020 and March 2021, we recruited 10 individuals that experienced PCR-
90 confirmed COVID-19 prior to vaccination and collected blood samples before and after a standard
91 two-dose BNT162b2 vaccine regimen (Table 1) and 20 age and sex matched with no self-reported
92 history of prior COVID-19 infection, verified by negative nucleocapsid ELISA, and collected blood
93 samples before and after vaccination. We then measured and compared serum neutralizing titers
94 in for these two groups using a live virus focus reduction neutralization test (FRNT) (Figure 1A-
95 B). Serum neutralizing titers increased for both groups pre- and post-vaccination and were
96 significantly higher among those with prior infection compared with vaccination for all strains
97 tested, including ancestral strain of SARS-CoV-2 (WA1) as well as the early VOCs Alpha, Beta,
98 and Gamma (Figure 1C). These results suggested that hybrid immunity from the combination of
99 vaccination and natural infection may result in meaningfully improved neutralizing serum antibody
100 titers.

101 ***A cross-sectional cohort of hybrid immune individuals including both prior infection and*** 102 ***vaccine breakthrough.***

103 To more comprehensively study our initial results suggesting infection followed by vaccination
104 elicited higher levels of SARS-CoV-2 specific antibodies compared to vaccination alone, we next
105 expanded on our cohort by recruiting additional vaccinated persons with or without hybrid
106 immunity due to previous COVID-19 (Table 1). This larger hybrid immune group included 23
107 individuals with PCR-confirmed infections prior to vaccination and 23 with vaccine breakthrough
108 infections, as both vaccination/infection histories have been shown to provide similar levels of
109 serological immunity.¹¹ To assure a more uniform comparison, sera were collected less than 60
110 days following vaccination or PCR-confirmed breakthrough infection. The participants with
111 infection prior to vaccination had all contracted COVID-19 during the pre-VOC era and are thus
112 believed to have been infected with ancestral SARS-CoV-2 variants, while breakthrough cohort
113 participants were recruited after the emergence of the VOCs, but prior to the Omicron era (Figure
114 1D). Using a subset of subjects for whom appropriate samples were available, viral sequences
115 were obtained from 17 of 23 breakthrough participants with showing that the majority of infections
116 were caused by the Alpha and Delta VOCs (Table 2).

117 ***Elevated antibody levels and neutralizing titers with hybrid immunity.***

118 We next measured spike-specific antibody levels for our larger cohort with a series of ELISA
119 experiments. Against purified RBD protein, total antigen-specific antibody levels increased 3.6-
120 fold with hybrid immunity compared to vaccine only (Figure 2A). Class-specific ELISAs showed
121 that this was primarily driven by improvements in IgG levels, which increased 3.7-fold (Figure 2B),
122 while the less abundant IgA improved by 3.2-fold (Figure 2C), and IgM levels showed no
123 significant difference between groups (Figure 2D). Total antibody levels against the full-length

124 spike protein, which includes the entire S1 and S2 domains were also improved with hybrid
125 immunity by 3.1-fold (Figure 2E).

126 Similarly, neutralizing antibody titers against SARS-CoV-2 and every SARS-CoV-2 variant tested
127 rose significantly in the hybrid immune group compared to vaccination alone (Figure 2F).
128 Neutralizing titers improved by 8.4-fold against WA1, 12.5-fold against Alpha, 22.7-fold against
129 Beta, 9.6-fold against Delta, 19.0-fold against Omicron BA.1, and 13.3-fold against Omicron BA.2.
130 The largest fold-increases were seen against the most vaccine resistant variants, Beta and
131 Omicron (BA.1 and BA.2). Further, it appears that these increases were not restricted to variants
132 with which the cohort was experienced, as all samples were collected prior to the emergence of
133 Omicron.

134 **Improved antibody quality among hybrid immune individuals.** To assess the breadth of the
135 neutralizing antibody response, we then looked at the relative ability to neutralize variants. This
136 was measured by dividing the neutralizing titer for each variant by the neutralizing titer for WA1.
137 For the Alpha and Beta variants, the hybrid immunity cohort showed greater cross-reactivity
138 compared to vaccine only cohort and moves closer to equal neutralization compared to WA1
139 (Figure 3A and 3B). The difference does not appear to be as large for Delta (Figure 3C), while
140 cross-neutralization against Omicron BA.1 and BA.2 did appear greater, but with cross-reactivity
141 most marked among those with higher titers (Figure 3D and 3E). This is quantified by the cohort
142 geometric mean variant cross-neutralization scores, which showed significantly greater cross-
143 reactivity for all variants except for Delta (Figure 3F and supplemental figure 1).

144 To assess the potency of the neutralizing antibody responses, we then calculated the neutralizing
145 potency index (NPI) for the individuals in each cohort against each variant. The NPI is the
146 neutralizing titer divided by the quantity of full-length spike specific total antibody levels as
147 measured by ELISA. NPI scores indicate the efficiency with which antigen-specific antibodies
148 neutralize virus on a per total antibody basis in which higher scores indicate that fewer antibodies
149 are necessary to achieve a given neutralization titer. We found that the NPI of hybrid immune
150 individuals increased significantly for all variants tested, with indexes of 2.7-fold (WA1), 4.0-fold
151 (Alpha), 7.2-fold (Beta), 3.0-fold (Delta), 6.1-fold (Omicron BA.1), and 4.2-fold (Omicron BA.2),
152 indicating a significant improvement in the neutralizing efficiency of the antibodies produced by
153 hybrid immunity compared to vaccination alone (Figure 3G).

154 **The interval between vaccination and natural infection dictates neutralizing titer levels.** The
155 hybrid immune cohort includes individuals who developed COVID-19 between 40 and 404 days
156 post-vaccination, as well as individuals who were vaccinated between 35 and 283 days after
157 testing positive for COVID-19. This range of hybrid exposure intervals allowed us to determine
158 the impact of time intervals on the resulting neutralizing antibody response. We also characterized
159 the correlation between antibody levels and neutralizing titers with our demographic data on age,
160 exposure interval, sex, and the time from last exposure to sample collection. Only neutralizing
161 antibody titers and antibody levels were significantly correlated with exposure interval. The
162 strongest correlations were seen for full-length spike-specific antibody level, as well as
163 neutralization of WA1, Alpha, Beta, Delta, Omicron BA.1 and Omicron BA.2 (Figure 4A-G).

164 The magnitude of increase seen over time was also different for each of the variants. Using linear
165 regression, we found the neutralizing titer against WA1 increased 5.3-fold by day 400 (Figure 4).
166 This increase was 4.8-fold for Alpha, 11.5-fold for Beta, 11.2-fold for Delta, 17.6-fold for Omicron
167 BA.1, and 14.3-fold for Omicron BA.2. The largest increases were seen against the more
168 contemporary variants, which also tend to be more vaccine resistant (Figure 2F). To validate that
169 these trends are not an artifact of linear regression, we also subdivided the cohort into 100-day
170 exposure interval bins, which recapitulated the previous findings (Figure 4H). Steady increases
171 are seen each 100 days, resulting in a final increase of 4.2-fold against WA1, 4.1-fold against

172 Alpha, 9.6-fold against Beta, 7.1-fold against Delta, 12.5-fold against Omicron BA.1, and 10.7-
173 fold against Omicron BA.2 between the 35-100 and 300-404 day exposure interval groups. Both
174 methods of analysis found a large and significant improvement in neutralizing antibody titers
175 occurs over an increased duration between the antigen exposures provided by vaccination and
176 natural infection. Further, these correlations were maintained when measured separately for
177 individuals with infection prior to vaccination and individuals with vaccine breakthrough infections
178 (Supplemental figures 2 and 3). Observed separately, neutralizing titers from individuals from the
179 breakthrough group appeared to increase faster than those in the prior infection group, but no
180 statistically significant difference could be measured. RBD-specific total antibody and IgG levels
181 correlated less strongly, while RBD-specific IgA and IgM did not correlate significantly with
182 exposure interval (Supplemental figure 4).

183 We then assessed for interactions between exposure interval and other variables that could
184 confound our analyses, including age, sex, or the time between final antigen exposure (either
185 vaccination or COVID-19 infection) and serum sample collection, all of which have been
186 previously shown to affect antibody levels.^{4,23,24} As expected, titers weakly correlated with age
187 and sex, but did not approach the relative contribution of exposure interval (Figure 4I).
188 Collection interval was not significantly correlated with any variable, likely due to our strict 60-day
189 limit on collection interval for inclusion in the study.

190 ***Variant cross-neutralization improves with greater exposure intervals.*** After observing the
191 improvements in variant cross-neutralization between hybrid immunity and vaccine only, we
192 thought to determine whether there was an equivalent dependence on the exposure interval
193 duration. Alpha is the least vaccine resistant variant and did not improve relative to WA1 because
194 it started at a ratio of 1 from the beginning (Figure 5A). For the more vaccine resistant variants,
195 which started well below 1, all saw increased variant cross-neutralization with increasing exposure
196 interval (Figure 5B-E). This indicates that the neutralizing antibody response is becoming more
197 broadly neutralizing over time, between exposures. No significant trends were seen with NPI over
198 time (Supplemental figure 5). This indicates that while the variant cross-reactivity is increasing
199 with longer exposure intervals, the proportion of antibodies which are capable of neutralization is
200 maintained.

201 Discussion

202 This study reports superior variant-neutralizing serum antibody titers with hybrid immunity from
203 combined vaccination and natural infection compared to vaccination alone. It further shows that
204 longer delays, up to at least 400 days, between vaccination and infection result in the largest
205 improvements in titers as well as better cross-neutralization of variants. The greatest increases
206 were seen against BA.1 Omicron, which is noteworthy because the samples used in this study
207 were collected prior to BA.1 emergence. In fact, half of the study participants were infected in the
208 pre-vaccine era, before the emergence of any VOCs.

209 In our cohort, infection alone provided poor neutralizing antibody responses, while two-dose
210 mRNA vaccination provided robust responses against original SARS-CoV-2 and the early
211 variants, but very poor neutralization of Omicron. Hybrid immunity has been shown previously to
212 result in greater humoral responses than two-dose vaccination,¹⁰⁻¹³ and our study expands upon
213 this by identifying the hybrid exposure interval (the time between infection and vaccination) as an
214 important factor in determining the strength of the neutralizing response. This was also recently
215 suggested in a study of breakthrough cases over intervals up to 100 days.¹⁹ The finding that this
216 effect extends to all hybrid immunity, including infection prior to vaccination is interesting because
217 it suggests that there is nothing inherently different about the order of two different exposure
218 modes (vaccination and infection) from the standpoint of neutralizing antibody development.

219 Further, because our prior infection group was never exposed to variant spike protein, it suggests
220 that many of the conserved epitopes that the memory response develops around are present and
221 recognizable on both the original strain of SARS-CoV-2 and every VOC including Omicron-BA.1.
222 This hypothesis is consistent with previous work has shown that memory B cells generated by
223 infection with original SARS-CoV-2 can recognize the variants,²⁵ and that germinal center
224 responses can continue for an extended period that improve cross-reactivity.^{26–28} Further, a recent
225 study found that recruitment of B cells to germinal centers is controlled by the balance of existing
226 antibody titers and availability of antigen,²⁹ suggesting that antibody waning may play a direct role
227 in broadening the antibody response over time. However, an alternative explanation is that each
228 of the two types of hybrid immunity increase via distinct mechanisms. For instance, breakthrough
229 infections may be more severe after longer intervals due to antibody waning in the interim, and
230 more severe infections may lead to greater final titers. Conversely, for infection prior to
231 vaccination, it is possible that high titers from shorter intervals result in poorer vaccine responses
232 than at later timepoints. Neither of these alternative hypotheses explain the observation of
233 improved variant cross-reactivity after longer intervals.

234 The results of this study demonstrate gradually improving memory responses to SARS-CoV-2
235 infection and vaccination, consistent with previous studies on the importance of an increased
236 interval between the first two vaccine doses in achieving higher antibody levels.^{17,18,20,30} While
237 booster vaccination has been shown to improve vaccine efficacy, there are relatively few studies
238 that have focused on the effects of different boosting intervals.^{31,32} Currently, fourth doses are
239 being offered to some groups in many parts of the world, and while early results are promising, it
240 remains to be seen if continued boosting results in long-term benefits or simply a transitory bump
241 in protective antibody levels.^{33,34}

242 Some studies have pointed to evidence of improved durability of hybrid immune
243 responses,^{12,13,35,36} which may be greater than that provided by boosters,³⁷ but further studies are
244 needed to establish whether vaccines which can elicit the same level of response and durability
245 provided by hybrid immunity; perhaps the best strategy for long-term protection will involve
246 addition of alternative vaccine types that better mimic natural infection. While hybrid immunity
247 currently appears to offer the strongest and possibly most durable protection, intentional infection
248 with natural COVID-19 as a means to achieve immunity is not a reasonable public health
249 approach given the risks of severe illness, long-term complications, and death that can result from
250 real SARS-CoV-2 infection.³⁸ To the contrary, our results support increased access to vaccines.
251 Demonstration that longer infection-vaccination intervals improve antibody responses implies that
252 even greatly delayed vaccination will yield sizeable benefits, particularly against emerging
253 vaccine-resistant variants. Simultaneously, our results point to a future where inevitable vaccine
254 breakthrough infections would be expected to help build a reservoir of population-level immunity
255 that can help blunt future waves and reduce the opportunity for further viral evolution.

256 **Methods**

257 **Cohort**

258 The longitudinal cohort participants were enrolled at Oregon Health & Science University (OHSU)
259 immediately after receiving their first dose of the BNT162b2 COVID-19 vaccine. A pre-vaccination
260 blood sample was collected at this time. Participants received a second vaccine dose between
261 20 and 32 days following the first dose, then returned between 10 and 30 days later for follow up,
262 at which time a post-vaccination blood sample was collected.

263 The cross-sectional cohort was comprised of health care workers who were enrolled at OHSU,
264 and individuals were selected from a previously established cohort based on the following

265 criteria:¹¹ Individuals who experienced COVID-19 prior to vaccination were included if serum
266 samples were collected less than 60 days after their second vaccine dose. Vaccinated individuals
267 who experienced vaccine breakthrough COVID-19 infections were included if serum samples
268 were collected less than 60 days after the date of receiving a positive PCR-based COVID-19 test.
269 Vaccinated individuals with no history of COVID-19 (vaccine only) were selected based on age,
270 sex, days between vaccine doses, and days between final vaccine dose and sample collection in
271 order to match the hybrid immune (combined prior infection and breakthrough) group as closely
272 as possible.

273 For all participants, 4-6 mL whole blood samples were collected and then centrifuged at 1000xg
274 for 10 minutes to isolate sera. Sera were aliquoted, heat inactivated at 65°C for 30 minutes, and
275 frozen at -20°C until needed for laboratory tests.

276 Enzyme linked Immunosorbent Assays (ELISA)

277 ELISA experiments were performed as previously described.¹¹ Briefly, 96-well plates were coated
278 overnight at 4°C with 1 µg/mL recombinant SARS-CoV-2 spike receptor binding domain (RBD)
279 protein, or recombinant full-length SARS-CoV-2 spike protein. Plates were washed in phosphate
280 buffered saline (PBS) with 0.05% Tween-20 (PBST) and blocked with PBST with 5% milk powder
281 (dilution buffer) for one hour at room temperature (RT). Four-fold serum dilutions were prepared
282 in dilution buffer starting at 1:50 for IgG/A/M, IgG, and IgA and 1:25 for IgM, then incubated at RT
283 for an hour. Plates were then washed three times and incubated with secondary antibody in
284 dilution buffer for another hour at RT. The secondary antibodies used were 1:10,000 α-IgG/A/M-
285 HRP (Invitrogen, A18847), 1:3,000 α-IgA-HRP (Biolegend, 411002), 1:3,000 α-IgG-HRP (BD
286 Biosciences, 555788), and 1:3,000 α-IgM-HRP (Bethyl Laboratories, A80-100P). Plates were
287 washed three more times with PBST and developed with o-phenylenediamine (OPD) for 20
288 minutes then stopped with 1N HCl. Absorbance was measured at 492nm on a CLARIOstar plate
289 reader and normalized by subtracting the average of negative control wells and dividing by the
290 highest concentration from a positive control serum. The serum dilution that resulted in half-
291 maximal binding was calculated by fitting normalized absorbance values to a dose-response
292 curve as previously described,³⁹ and inverse serum dilution values were reported as 50% effective
293 concentrations (EC₅₀).

294 Viruses

295 SARS-CoV-2 clinical isolates were obtained from BEI Resources: Isolate USA-WA1/2020
296 [wildtype] (BEI Resources NR-52281); Isolate USA/CA_CDC_5574/2020 [Alpha - B.1.1.7] (BEI
297 Resources NR-54011); Isolate hCoV-54 19/South Africa/KRISP-K005325/2020 [B.1.351] (BEI
298 Resources NR-54009); Isolate hCoV-19/Japan/TY7-503/2021 [P.1] (BEI Resources NR-54982);
299 and Isolate hCoV-19/USA/PHC658/2021 [B.1.617.2] (BEI Resources NR-55611). Isolates were
300 propagated and titrated in Vero E6 cells as previously described.¹¹ Vero E6 cells were seeded in
301 tissue culture flasks such that they were 70-90% confluent at the time of infection. In minimal
302 volume of Opti-MEM plus 2% FBS, flasks were infected at an MOI of 0.05 for 1 hour at 37°C
303 before adding additional DMEM plus 10% FBS, 1% penicillin-streptomycin, 1% nonessential
304 amino acids (complete media) to manufacturer's recommended culture volume. Flasks were
305 incubated until cytopathic effects were observed, 24-96 hours. Collected supernatants were
306 centrifuged at 1,000xg for 10 minutes, aliquoted and frozen at -80°C. Titrations were performed
307 by preparing 10-fold dilutions of frozen aliquots and incubating 30 µL for 1 hour on 96-well plates
308 of sub-confluent Vero E6 cells before adding Opti-MEM plus 2% FBS, 1% methylcellulose
309 (overlay media). Titration plates were incubated for 24 hours, or 48 hours for Omicron
310 sublineages, then fixed with 4% formaldehyde for 1 hour. The formaldehyde was removed, and

311 plates were blocked for 30 minutes at RT with PBS plus 0.1% saponin, 0.1% bovine serum
312 albumin (perm buffer). The blocking buffer was then replaced with 1:5,000 anti-SARS-CoV-2
313 alpaca serum (Capralogics Inc.) in perm buffer and incubated overnight at 4°C. The plates were
314 then washed three times for 5 minutes in PBST and incubated with 1:20,000 anti-alpaca-HRP
315 (Novus, NB7242) for 2 hours at RT. Plates were then washed three more times with PBST for 5
316 minutes each, then developed with TrueBlue (SeraCare 5510-0030) for 30 minutes or until foci
317 were strongly stained. Wells were imaged with a CTL ImmunoSpot Analyzer. Focus counts were
318 used to calculate the concentration of focus forming units (FFU) in the virus stock aliquots.

319 **Focus Reduction Neutralization Test (FRNT)**

320 Focus forming assays were performed as previously described.¹¹ Briefly, Vero E6 (ATCC CRL-
321 1586) cells were plated at 20,000 cells/well 16-24 hours before starting the assay. Sera were
322 diluted in Opti-MEM plus 2% FBS (dilution media). Virus stocks were diluted to 3,333 FFU/mL
323 (determined by titration) and combined 1:1 with serum dilutions. Initial serum dilutions started at
324 1:10, which became 1:20 after the 1:1 dilution with virus, and 30 µL of serum/virus mixture was
325 added to each well for 1 hour at 37°C. Dilution series were performed in duplicate with one no
326 serum control well for each replicate. Overlay media was added to each well and plates were
327 incubated for 24 hours, or 48 hours for Omicron sublinages. Plates were fixed with 4%
328 formaldehyde for 1 hour and then stained similarly to titration plates as described above. Foci in
329 well images were counted with Viridot (1.0) in R (3.6.3).⁴⁰ Percent neutralization for each well was
330 calculated relative to the average of all no serum control wells on each plate. The serum dilution
331 that resulted in 50% neutralization was calculated by fitting percent neutralization values to a
332 dose-response curve as previously described,³⁹ and inverse serum dilution values were reported
333 as 50% focus reduction neutralization test (FRNT₅₀) titers. For each sample, FRNT₅₀ values were
334 first calculated separately for each duplicate and verified to be within 4-fold. Combined FRNT₅₀
335 values were calculated for all samples which passed this test, and samples which failed this test
336 were excluded from further analysis.

337 **Statistical Analysis**

338 The limit of detection (LOD) of each assay was defined by the lowest dilution tested, values below
339 the LOD were set to LOD – 1 for both ELISA and FRNT experiments. Graphing and statistical
340 tests were performed in GraphPad Prism. Pairwise comparisons were performed using the Mann-
341 Whitney U test. The Holm-Šidák multiple comparison correction was used anywhere data are
342 shown on a continuous X-axis. Simple linear regression was performed on log transformed EC₅₀
343 and FRNT₅₀ values and significance was determined with an F test with a zero-slope null
344 hypothesis. Correlations were calculated using Pearson's method. All P values are two-tailed and
345 $P=0.05$ was the cutoff for significance.
346

347 **Study Approval**

348 This study was conducted in accordance with the Oregon Health & Science University Institutional
349 Review Board (IRB # 00022511), and written informed consent was obtained from all participants.

350

351 **Author Contributions**

352 TAB, HCL, WBM, MEC, FGT conceptualization. TAB, HCL, SKM, ZLL, DXL methodology. TAB
353 software. TAB, HCL, SKM, DS, WBM, FGT, MEC validation. TAB, DS, WBM formal analysis.
354 TAB, HCL, SKM, DS investigation. WBM, MEC, FGT resources. TAB, HCL, DS data curation.


355 TAB writing – original draft. TAB, HCL, SKM, DS, ZLL, DXL, WBM, MEC, FGT writing – review &
356 editing. TAB, DS visualization. TAB, WBM, MEC, FGT supervision. TAB, WBM, MEC, FGT project
357 administration. TAB, WBM, MEC, FGT funding acquisition.

358

359 **Acknowledgements**

360 This study was funded by a grant from the M. J. Murdock Charitable Trust (to MEC), an
361 unrestricted grant from the OHSU Foundation (to MEC), the NIH training grant T32HL083808 (to
362 TAB), NIH grant R011R01AI141549-01A1 (to FGT), OHSU Innovative IDEA grant 1018784 (to
363 FGT), and NIH grant R01AI145835 (to WBM).


364 We thank the participants of this study for their contribution. We additionally thank the OHSU
365 COVID-19 serology study team and the OHSU department of Occupational Health for recruiting
366 participants and collecting samples, and the OHSU clinical laboratory under the direction of D.
367 Hansel and X. Qin for SARS-CoV-2 testing and reporting.



368

369 **Figure 1: Longitudinal cohort of previously infected vaccinees shows improved variant**
 370 **neutralization compared to vaccination alone**


371 Representative focus reduction neutralization test (FRNT) results showing wells infected with live
 372 SARS-CoV-2 with the addition of serially diluted serum which were stained and counted (**A**).
 373 Representative focus reduction neutralization curve showing the average neutralization of
 374 duplicates as a percent of no serum controls and fit to a dose-response curve to find the 50%
 375 neutralizing titer (FRNT₅₀) (**B**). Live virus FRNT₅₀ measurements against original SARS-CoV-2
 376 (WA1) and the Alpha, Beta, and Gamma variants before and after vaccination (**C**). Timeline
 377 depicting the prevalence of impactful variants in the study location, Oregon, USA (**D**).⁴¹ Vaccine-
 378 only participants are represented by red circles and hybrid immune participants by cyan squares.
 379 Error bars represent the geometric mean with 95% confidence intervals. P values in C show the
 380 result of Mann-Whitney U tests. All P values are two-tailed and 0.05 was considered significant.
 381 For panel C, n=20 for the vaccine only group and n=10 for the prior infection group.



382

383 **Figure 2: Cross-sectional cohort of individuals with hybrid immunity show improved**
384 **antibody levels and variant neutralization**


385 Levels of SARS-CoV-2 spike receptor binding domain (RBD)-specific total (IgG/A/M) antibody
386 (A), IgG (B), IgA (C), and IgM (D). Levels of full-length spike-specific total antibody (E). Live virus
387 FRNT₅₀ measurements against original SARS-CoV-2 (WA1) and the Alpha, Beta, Delta, Omicron
388 (BA.1), and Omicron (BA.2) variants (F). Vaccine only participants are represented by red circles
389 and hybrid immune participants by blue squares. Error bars represent the geometric mean with
390 95% confidence intervals. P values in A-F show the result of Mann-Whitney U tests. All P values
391 are two-tailed and 0.05 was considered significant. For panels A-F, n=20 for the vaccine only
392 group and n=46 for the hybrid immunity group.



393

394 **Figure 3: Antibody quality and variant cross-neutralization are improved with hybrid**
 395 **immunity**


396 Individual neutralizing FRNT₅₀ values against WA1 versus Alpha (**A**), Beta (**B**), Delta (**C**), Omicron
 397 (BA.1) (**D**), and Omicron (BA.2) (**E**). Diagonal broken line indicates equal neutralization of WA1
 398 and variant in A-D. Relative neutralization, calculated as the neutralizing titer against each of the
 399 variants divided by the neutralizing titer against WA1 (**F**). Neutralizing potency index indicates the
 400 neutralizing FRNT₅₀ against the indicated variant divided by full-length spike protein EC₅₀ antibody
 401 levels (**G**). Vaccine-only participants are represented by red circles and hybrid immune
 402 participants by blue squares. Error bars represent the geometric mean with 95% confidence
 403 intervals. P values in F-G show the result of Mann-Whitney U tests with the Holm-Šidák multiple
 404 comparison correction. All P values are two-tailed and 0.05 was considered significant. For panels
 405 A-G, n=20 for the vaccine only group and n=46 for the hybrid immunity group.



406

407 **Figure 4: Exposure interval determines strength of hybrid immunity**

408 Comparison of exposure interval, the time between first and last antigen exposure, with full-length
 409 spike EC₅₀ antibody levels (**A**), and neutralization of WA1 (**B**), Alpha (**C**), Beta (**D**), Delta (**E**),
 410 Omicron (BA.1) (**F**), and Omicron (BA.2) (**G**). Neutralization of variants binned by exposure
 411 interval in days (**H**). Heat map of correlation significance between explanatory and response
 412 variables (**I**). Individual values in A-G are shown as filled circles and the shaded area indicates
 413 the linear fit with 95% confidence interval. R^2 is indicated for each curve fit. P values in A-G show
 414 the result of an F-test using a zero slope null hypothesis, P values in H show the result of Mann-
 415 Whitney U tests with the Holm-Šídák multiple comparison correction, and colors in I represent the
 416 P values of pearson r correlation coefficients according to the scale bar. All P values are two-
 417 tailed and 0.05 was considered significant. For panels A-G and I, n=46. For panel H, n=7 for the
 418 35-100 days group, n=10 for the 101-200 days group, n=18 for the 201-300 days group, and n=11
 419 for the 301-404 days group.



420

421 **Figure 5: Exposure interval increases variant cross-neutralization by hybrid immune sera**

422 Comparison of exposure interval, the time between first and last antigen exposure, with relative
423 neutralization of Alpha (A), Beta (B), Delta (C), Omicron (BA.1) (D), and Omicron (BA.2) (E) over
424 wildtype (WA1). Individual values are shown as filled circles and the shaded area indicates the
425 linear fit with 95% confidence interval. R² is indicated for each curve fit. P values show the result
426 of an F-test using a zero slope null hypothesis. All P values are two-tailed and 0.05 was
427 considered significant. For panels A-E, n=46.

428 **Table 1: Demographics**

		Pre/post vaccination (longitudinal)			Post vaccine (cross-sectional)				
		All	Vaccine only	Prior infection	All	Hybrid immunity			
						Vaccine only	Prior infection	Breakthrough infection	
Cohort size	n	30	20	10	66	20	46	23	23
Age	Years - median [range]	39.5 [23-63]	41.5 [25-63]	36.5 [23-61]	39.5 [23-73]	39.5 [23-63]	40 [23-73]	47 [23-73]	38 [24-63]
Sex	Male - n (%)	10 (33)	6 (30)	4 (40)	18 (27)	3 (15)	15 (33)	10 (43)	5 (22)
	Female - n (%)	20 (67)	14 (70)	6 (60)	48 (73)	17 (85)	31 (67)	13 (57)	18 (78)
disease severity	Asymptomatic - n (%)	-	-	2 (20)	-	-	3 (7)	3 (13)	0 (0)
	Mild - n (%)	-	-	7 (70)	-	-	39 (85)	19 (83)	20 (87)
	Moderate - n (%)	-	-	1 (10)	-	-	3 (7)	1 (4)	2 (9)
between vaccine doses	Days - median [range]	22 [20-32]	21 [21-32]	22 [20-25]	21 [17-45]	21 [21-25]	21 [17-45]	22 [18-45]	21 [17-32]
exposure interval*	Days - median [range]	-	-	98 [40-303]	-	-	221 [35-404]	299 [40-404]	215 [35-238]
collection interval**	Days - median [range]	17 [10-28]	16 [10-25]	18 [14-28]	23 [10-53]	19.5 [10-28]	25.5 [10-53]	25 [11-53]	27 [10-49]


429

430 **Table 2: variants of infections**

	N	%
Prior infection	23	100
Not sequenced*	23	100
Breakthrough infection	23	100
Alpha	4	17
Beta	1	4
Gamma	2	9
Delta	10	43
Not sequenced**	6	26

431


432 Supplementary information:



433

434 **Supplemental figure 1: Variant cross-neutralization by hybrid immune sera is improved**
435 **compared to vaccination alone**

436 Individual neutralizing FRNT₅₀ values for each of the variants against WA1 for the hybrid immune
437 group (A), and two-dose vaccine only group (B). Diagonal broken line indicates equal
438 neutralization of WA1 and variant. For panels A-B, n=20 for the vaccine only group and n=46 for
439 the hybrid immunity group.




440

441 **Supplemental figure 2: Infection prior to vaccination group neutralizing responses**
442 **correlate with exposure interval**

443 Comparison of exposure interval, the time between first and last antigen exposure, among
444 individuals with SARS-CoV-2 infection prior to vaccination. Correlations are shown for full-length
445 spike EC_{50} antibody levels (**A**), and neutralization of WA1 (**B**), Alpha (**C**), Beta (**D**), Delta (**E**),
446 Omicron (BA.1) (**F**), and Omicron (BA.2) (**G**). Individual values are shown as filled circles and the
447 shaded area indicates the linear fit with 95% confidence interval. R^2 is indicated for each curve fit
448 and P values show the result of an F-test using a zero slope null hypothesis. All P values are two-
449 tailed and 0.05 was considered significant. For panels A-G, $n=23$.

Infection following infection (breakthrough)




450

451 **Supplemental figure 3: Vaccine breakthrough group neutralizing responses correlate with** 452 **exposure interval**

453 Comparison of exposure interval, the time between first and last antigen exposure, among
454 individuals with vaccine breakthrough infections. Correlations are shown for full-length spike EC₅₀
455 antibody levels (A), and neutralization of WA1 (B), Alpha (C), Beta (D), Delta (E), Omicron (BA.1)
456 (F), and Omicron (BA.2) (G). Individual values are shown as filled circles and the shaded area
457 indicates the linear fit with 95% confidence interval. R² is indicated for each curve fit and P values
458 show the result of an F-test using a zero slope null hypothesis. All P values are two-tailed and
459 0.05 was considered significant. For panels A-G, n=23.

Antibody levels vs. exposure interval




460

461 **Supplemental figure 4: Other antibody isotypes correlate less well with exposure interval**

462 Comparison of exposure interval, the time between first and last antigen exposure, with total
463 (IgG/A/M) spike RBD (A), IgG (B), IgA (C), and IgM (D) EC₅₀ antibody levels. Individual values
464 are shown as filled circles and the shaded areas indicate the linear fit with 95% confidence
465 interval. R^2 is indicated for each curve fit and P values show the result of an F-test using a zero
466 slope null hypothesis. All P values are two-tailed and 0.05 was considered significant. For panels
467 A-D, n=46.

468

Neutralizing potency index vs. exposure interval



469

470 Supplemental figure 5: Neutralizing potency index does not correlate with exposure 471 interval

472 Comparison of exposure interval, the time between first and last antigen exposure, with
473 neutralization potency index (FRNT₅₀ / full-length spike EC₅₀) of wildtype (WA1) (A), Alpha (B),
474 Beta (C), Delta (D), Omicron (BA.1) (E), and Omicron (BA.2) (F). Individual values are shown as
475 filled circles and the shaded area indicates the linear fit with 95% confidence interval. R² is
476 indicated for each curve fit. P values show the result of an F-test using a zero slope null
477 hypothesis. All P values are two-tailed and 0.05 was considered significant. For panels A-F, n=46.

478 **References**

- 479 1. Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in
480 real time. *The Lancet Infectious Diseases* **20**, 533–534 (2020).
- 481 2. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2
482 through Nov 14, 2021: a statistical analysis. *The Lancet* (2022) doi:10.1016/S0140-
483 6736(22)00484-6.
- 484 3. Ritchie, H. *et al.* Coronavirus Pandemic (COVID-19). *Our World in Data* (2020).
- 485 4. Cohn, B. A., Cirillo, P. M., Murphy, C. C., Krigbaum, N. Y. & Wallace, A. W. SARS-CoV-2
486 vaccine protection and deaths among US veterans during 2021. *Science* **375**, 331–336
487 (2022).
- 488 5. Rosenberg, E. S. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination
489 Status — New York, May 3–July 25, 2021. *MMWR Morb Mortal Wkly Rep* **70**, (2021).
- 490 6. Tartof, S. Y. *et al.* Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a
491 large integrated health system in the USA: a retrospective cohort study. *Lancet* **398**, 1407–
492 1416 (2021).
- 493 7. Goldberg, Y. *et al.* Waning Immunity after the BNT162b2 Vaccine in Israel. *N Engl J Med* **385**,
494 e85 (2021).
- 495 8. Choi, A. *et al.* Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in
496 healthy adults: an interim analysis. *Nat Med* 1–7 (2021) doi:10.1038/s41591-021-01527-y.
- 497 9. Garcia-Beltran, W. F. *et al.* mRNA-based COVID-19 vaccine boosters induce neutralizing
498 immunity against SARS-CoV-2 Omicron variant. *Cell* (2022) doi:10.1016/j.cell.2021.12.033.
- 499 10. Wratil, P. R. *et al.* Three exposures to the spike protein of SARS-CoV-2 by either infection or
500 vaccination elicit superior neutralizing immunity to all variants of concern. *Nat Med* **28**, 496–
501 503 (2022).
- 502 11. Bates, T. A. *et al.* Vaccination before or after SARS-CoV-2 infection leads to robust humoral
503 response and antibodies that effectively neutralize variants. *Science Immunology* (2022)
504 doi:10.1126/sciimmunol.abn8014.
- 505 12. Pilz, S., Theiler-Schwetz, V., Trummer, C., Krause, R. & Ioannidis, J. P. A. SARS-CoV-2
506 reinfections: Overview of efficacy and duration of natural and hybrid immunity. *Environ Res*
507 **209**, 112911 (2022).
- 508 13. Goldberg, Y. *et al.* Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.
509 *New England Journal of Medicine* **0**, null (2022).
- 510 14. Cromer, D. *et al.* Neutralising antibody titres as predictors of protection against SARS-CoV-2
511 variants and the impact of boosting: a meta-analysis. *The Lancet Microbe* **3**, e52–e61 (2022).
- 512 15. Bates, T. A. *et al.* Antibody Response and Variant Cross-Neutralization After SARS-CoV-2
513 Breakthrough Infection. *JAMA* (2021) doi:10.1001/jama.2021.22898.
- 514 16. Rössler, A., Riepler, L., Bante, D., von Laer, D. & Kimpel, J. SARS-CoV-2 Omicron Variant
515 Neutralization in Serum from Vaccinated and Convalescent Persons. *New England Journal*
516 *of Medicine* **386**, 698–700 (2022).
- 517 17. Payne, R. P. *et al.* Immunogenicity of standard and extended dosing intervals of BNT162b2
518 mRNA vaccine. *Cell* **184**, 5699-5714.e11 (2021).
- 519 18. Hall, V. G. *et al.* Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral
520 immunity and induces robust T cell responses. *Nat Immunol* 1–6 (2022) doi:10.1038/s41590-
521 021-01126-6.
- 522 19. Miyamoto, S. *et al.* Vaccination-infection interval determines cross-neutralization potency to
523 SARS-CoV-2 Omicron after breakthrough infection by other variants. *Med* **3**, 249-261.e4
524 (2022).
- 525 20. Sanchez, S., Palacio, N., Dang, T., Ciucci, T. & Penaloza-MacMaster, P. Fractionating a
526 COVID-19 Ad5-vectored vaccine improves virus-specific immunity. *Science Immunology* **6**,
527 eabi8635 (2021).

- 528 21. Ferdinands, J. M. *et al.* Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against
529 COVID-19–Associated Emergency Department and Urgent Care Encounters and
530 Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance
531 — VISION Network, 10 States, August 2021–January 2022. *MMWR Morb. Mortal. Wkly. Rep.*
532 **71**, (2022).
- 533 22. Levin, E. G. *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over
534 6 Months. *New England Journal of Medicine* (2021) doi:10.1056/NEJMoa2114583.
- 535 23. Anastassopoulou, C. *et al.* Age and sex associations of SARS-CoV-2 antibody responses
536 post BNT162b2 vaccination in healthcare workers: A mixed effects model across two
537 vaccination periods. *PLOS ONE* **17**, e0266958 (2022).
- 538 24. Bates, T. A. *et al.* Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine
539 Immune Serum Samples. *JAMA* (2021) doi:10.1001/jama.2021.11656.
- 540 25. Lyski, Z. L. *et al.* SARS-CoV-2 specific memory B-cells from individuals with diverse disease
541 severities recognize SARS-CoV-2 variants of concern. *J Infect Dis* jia585 (2021)
542 doi:10.1093/infdis/jia585.
- 543 26. Sakharkar, M. *et al.* Prolonged evolution of the human B cell response to SARS-CoV-2
544 infection. *Science Immunology* **6**, (2021).
- 545 27. Turner, J. S. *et al.* SARS-CoV-2 mRNA vaccines induce persistent human germinal centre
546 responses. *Nature* **596**, 109–113 (2021).
- 547 28. Kim, W. *et al.* Germinal centre-driven maturation of B cell response to mRNA vaccination.
548 *Nature* 1–8 (2022) doi:10.1038/s41586-022-04527-1.
- 549 29. Tas, J. M. J. *et al.* Antibodies from primary humoral responses modulate the recruitment of
550 naive B cells during secondary responses. *Immunity* (2022)
551 doi:10.1016/j.immuni.2022.07.020.
- 552 30. Grunau, B. *et al.* Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals.
553 *JAMA* **327**, 279–281 (2022).
- 554 31. Zhao, X. *et al.* Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant.
555 *New England Journal of Medicine* **0**, null (2022).
- 556 32. Andrews, N. *et al.* Effectiveness of COVID-19 booster vaccines against COVID-19-related
557 symptoms, hospitalization and death in England. *Nat Med* **28**, 831–837 (2022).
- 558 33. Magen, O. *et al.* Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
559 *New England Journal of Medicine* **386**, 1603–1614 (2022).
- 560 34. Regev-Yochay, G. *et al.* Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against
561 Omicron. *New England Journal of Medicine* **386**, 1377–1380 (2022).
- 562 35. Epsi, N. J. *et al.* Understanding ‘hybrid immunity’: comparison and predictors of humoral
563 immune responses to SARS-CoV-2 infection and COVID-19 vaccines. *Clinical Infectious*
564 *Diseases* ciac392 (2022) doi:10.1093/cid/ciac392.
- 565 36. Nordström, P., Ballin, M. & Nordström, A. Risk of SARS-CoV-2 reinfection and COVID-19
566 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population
567 cohort study in Sweden. *The Lancet Infectious Diseases* **0**, (2022).
- 568 37. Vanshylla, K. *et al.* Durability of omicron-neutralising serum activity after mRNA booster
569 immunisation in older adults. *The Lancet Infectious Diseases* **22**, 445–446 (2022).
- 570 38. Al-Aly, Z., Bowe, B. & Xie, Y. Long COVID after breakthrough SARS-CoV-2 infection. *Nat*
571 *Med* 1–7 (2022) doi:10.1038/s41591-022-01840-0.
- 572 39. Bates, T. A. *et al.* Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2
573 vaccinated serum. *Nat Commun* **12**, 5135 (2021).
- 574 40. Katzelnick, L. C. *et al.* Viridot: An automated virus plaque (immunofocus) counter for the
575 measurement of serological neutralizing responses with application to dengue virus. *PLOS*
576 *Neglected Tropical Diseases* **12**, e0006862 (2018).
- 577 41. Hodcroft, E. B. CoVariants: SARS-CoV-2 Mutations and Variants of Interest.
578 <https://covariants.org/> (2021).